AshwinNAnanthakrishnanMDMPH
Gastroenterology • Boston, MAInflammatory Bowel Disease
Associate Professor of Medicine, Massachusetts General Hospital and Harvard Medical School.
Dr. Ananthakrishnan is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
165 Cambridge Street
Boston, MA 02114Phone+1 617-726-0267
Education & Training
Medical College of Wisconsin Affiliated HospitalsFellowship, Gastroenterology, 2007 - 2010- Medical College of Wisconsin Affiliated HospitalsResidency, Internal Medicine, 2004 - 2007
Jawaharlal Institute of Postgraduate Medical Education and ResearchClass of 2003
Certifications & Licensure
ME State Medical License 2021 - 2026
MA State Medical License 2010 - 2025
NH State Medical License 2021 - 2025
RI State Medical License 2021 - 2024
WI State Medical License 2005 - 2011- American Board of Internal Medicine Gastroenterology
Clinical Trials
- Effect of a Probiotic Mixture on the Gut Microbiome and Fatigue in Patients With Quiescent Inflammatory Bowel Disease Start of enrollment: 2017 Nov 13
- Multi-center Acute Severe Ulcerative Colitis Cohort Study (MASCC) Start of enrollment: 2018 Nov 10
Publications & Presentations
PubMed
- 51 citationsEtrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.David T. Rubin, Iris Dotan, Aaron DuVall, Yoram Bouhnik, Graham L. Radford-Smith
The Lancet. Gastroenterology & Hepatology. 2021-11-16 - 53 citationsEtrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, ran...Laurent Peyrin-Biroulet, Ailsa Hart, Peter Bossuyt, Millie D. Long, Matthieu Allez
The Lancet. Gastroenterology & Hepatology. 2021-11-17 - 2725 citationsHost-microbe interactions have shaped the genetic architecture of inflammatory bowel diseaseLuke Jostins, Stephan Ripke, Rinse K. Weersma, Richard H. Duerr, Dermot P.B. McGovern
Nature. 2012-11-01
Journal Articles
- CT-Visualized Colonic Mural Stratification Independently Predicts the Need for Medical or Surgical Rescue Therapy in Hospitalized Ulcerative Colitis PatientsMichael S Gee, Ashwin N Ananthakrishnan, Digestive Diseases and Sciences
- Dietary Gluten Intake and Risk of Microscopic Colitis Among US Women Without Celiac Disease: A Prospective Cohort StudyBenjamin Lebwohl, Paul Lochhead, Ashwin N Ananthakrishnan, Andrew T Chan, Kristin E Burke, James M Richter, Hamed Khalili, Nature
- Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative ColitisJay Luther, Francis Colizzo, Ashwin N Ananthakrishnan, Amar Vedamurthy, John J Garber, Hamed Khalili, Digestive Diseases and Sciences
- Join now to see all
Press Mentions
Does Bezlotoxumab Boost FMT Efficacy in IBD Patients with Recurrent CDI?November 11th, 2024- ACG/ASGE Task Force Identifies 19 Indicators for Achieving Quality GI EndoscopySeptember 11th, 2024
- New Guidelines Recommend Stool and Blood Tests to Monitor Ulcerative ColitisFebruary 24th, 2023
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
